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Abstract In contrast to the general model of cytokine-induced 
JAK/STAT signaling, tyrosine phosphorylation of the IL-5R )3 
chain seems to be dispensable for STAT activation in cells 
overexpressing exogenous STAT proteins. In this study we 
expressed IL-5 receptor mutants in 293 cells and studied IL-5-
induced endogenous STAT-dependent transcription. Our results 
indicate that: (a) tyrosine phosphorylation of the IL-5R /j chain 
is required for endogenous STAT5 activation, (b) multiple 
tyrosine residues are phosphorylated upon IL-5 stimulation, 
including Tyr5 7 7 , Tyr6 1 2 , Tyr6 9 5 , and Tyr7 5 0 , and (c) Tyr6 1 2 , 
Tyr6 9 5 , and Tyr7 5 0 are all capable of inducing activation of 
STAT5, demonstrating a high level of functional redundancy 
within the IL-5R )3 chain. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cytokines such as interleukin-5 (IL-5), IL-3 and granulo-
cyte macrophage colony-stimulating factor (GM-CSF) play a 
crucial role in the proliferation, differentiation, and activation 
of blood cells and their precursors [1,2]. IL-5 is essential for 
eosinophil proliferation and differentiation [3] and is the key 
regulator of survival, migration, and activation of mature eo-
sinophils [4-6]. The IL-5 receptor is composed of a specific IL-
5R a chain which is only expressed on eosinophils and baso-
phils [7] and a common Pc subunit that is shared with the 
receptors for IL-3 and G M - C S F [8]. Both the a and [3c chains 
are necessary for signal transduction by IL-5 [9-11]. 
IL-5 induces rapid and reversible tyrosine phosphorylation 
of cellular proteins in both hematopoietic cells and fibroblasts 
[6,9]. Tyrosine phosphorylated proteins include the (3c subunit 
itself and proteins that belong to the r a s -MAPK pathway and 
the JAK-STAT pathway [9,11-13]. Recent studies have shown 
that several tyrosine kinases of the Src-family, including 
p59/!/» [14] and p53/56^" [15], and others, such as Tec [16] 
and p93^es [17], are activated via the [3c subunit in different 
cellular systems. 
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The Janus tyrosine kinase JAK2 is activated in response to 
IL-3, IL-5, and G M - C S F and specifically associates with the 
membrane-proximal region of the [3 chain [12,18]. JAK2 then 
activates the transcription factors STAT1, STAT3 and 
STAT5, depending on the cell type studied [11,13,19]. A num-
ber of studies have suggested that activated JAKs can phos-
phorylate tyrosine residues within the cytokine receptor, pro-
viding specific binding sites for the SH2 domain of the STAT 
transcription factors. Support for this model has been ob-
tained from different receptor systems, including the IFN-y 
[20], IL-2 [21], IL-4 [22], IL-6 [23], IL-9 [24], erythropoietin 
(EPO) [25,26], and growth hormone (GH) receptors [27]. By 
contrast, we and others have shown that deletion mutants of 
the common |3 that lack tyrosine residues, can still activate 
STAT1 and STAT3 (when overexpressed in COS cells) [11] 
and STAT5 (when overexpressed in BA/F3 cells) [13], suggest-
ing that tyrosine phosphorylation is dispensable for STAT 
activation by IL-5. 
In this paper we report that multiple tyrosine residues in the 
IL-5R|3, including Tyr577 , Tyr612 , Tyr6 9 5 , and Tyr750 , can be 
phosphorylated upon IL-5 signaling. Tyrosine phosphoryla-
tion of either Tyr612 , Tyr695 , or Tyr750 is necessary and suffi-
cient for maximal endogenous STAT activation, showing the 
existence of a high level of functional redundancy within the 
IL-5R(3. 
2. Materials and methods 
2.1. Cell culture, reagents, and antibodies 
293, Rat-1, and 3T3 cells were cultured in Dulbecco's modified 
Eagle's medium (Gibco) supplemented with 8% heat-inactivated fetal 
calf serum (FCS). HL-60 cells were maintained in RPMI 1640 supple-
mented with 8% Hyclone serum (Gibco). Human IL-5 (hIL-5) was a 
kind gift of Dr. D. Fattah (Glaxo Wellcome Group Research, Steven-
age, UK). Polyclonal rabbit antibodies against the IL-5R (3 chain were 
produced by immunization of rabbits with the histidine-tagged extra-
cellular part of the IL-5R P chain; anti-phosphotyrosine monoclonal 
antibody (4G10) was obtained from UBI (Lake Placid, NY); mono-
clonal antibody against STAT1 (G16920) was obtained from Trans-
duction Laboratories (Lexington, KY); antibodies against STAT3 (K-
15), STAT5a (L-20) and STAT5b (C-17) were obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). 
2.2. Synthetic oligonucleotides and plasmid construction 
The following oligonucleotides were used in this study (only the 
upper strands are shown): the human ICAM-1 IRE (5'-AGCT-
TAGTTTCCGGGAAAGCAC-3'), the c-fos SIEm67 (5'-AGCTT-
CATTTCCCGTAAATCA-3'), the FcyRI (5'-AGCTTGAGATGTA 
TTTCCCAGAAAAGA-3') and the (3-casein (5'-AGCTTAGATTTC-
TAGGAATTCAA ATCA-3'). These oligonucleotides were multimer-
ized and cloned in the pBlCAT2 reporter. pSV-lacZ, expression vec-
tors for the IL-5R a and P chains and deletion constructs of the pc 
were described previously [11,28]. Site-directed mutagenesis was per-
formed as described by Kunkel [29]. 
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2.3. Transient transfection, immunoprecipitation, Western blot analysis 
and gel retardation assay 
Transient transfection experiments and CAT assays were performed 
as described previously [11,28]. Immunoprecipitation and Western 
blotting of STAT proteins from transfected 293 cells (20 cm2 dishes, 
Nunc) or HL-60 cells were performed as described previously [11]. 
Nuclear extracts were prepared from unstimulated and IL-5-stimu-
lated Rat-1 cells and 3T3 cells and assayed for STAT binding as 
described previously [11]. 
3. Results 
To determine the domains in the IL-5R (3 chain involved in 
the activation of endogenous STAT proteins, several trun-
cated forms (Fig. 1A) were transfected together with the IL-
5 receptor a subunit and a reporter containing FcyRI STAT 
binding sites in 293 cells. Fig. IB shows that truncation of the 
p chain down to amino acid 615 ((3615) did not affect the level 
of IL-5 induced CAT activity. Deleting the next 4 amino acids 
encompassing the tyrosine phosphorylation site YLSL ((3611) 
greatly reduced IL-5-induced CAT activity. A further reduc-
tion was observed using deletion mutant (3456, which contains 
only the first seven amino acids of the intracellular domain. 
Similar results were obtained in Rat-1 and 3T3 cells (not 
shown). This indicates that amino acids 611-615 and amino 
acids 581^456 are important for IL-5-induced endogenous 
STAT activation. 
In parallel, we tested IL-5-induced tyrosine phosphorylation 
of the (3c deletion constructs. In Fig. 1C it is shown that (3881 
(the full-length receptor), p763, P627, and P615 are heavily 
phosphorylated after IL-5 stimulation. A clear drop in phos-
phorylation was observed in constructs lacking Tyr612, like 
P581 and p611, suggesting that Tyr612 is phosphorylated. 
No tyrosine phosphorylation was observed in shorter con-
structs lacking Tyr577, like (3568 and P456, indicating that 
Tyr577 was also phosphorylated. Interestingly, this tyrosine 
residue is also phosphorylated in BA/F3 cells in response to 
GM-CSF [30]. The differences in the loading controls of Fig. 
1C are partially caused by the fact that the longer mutants are 
less well expressed compared to the shorter constructs. 
To determine which STAT was activated in 293 cells, we 
immunoprecipitated STAT1, STAT3, STAT5a and STAT5b 
from IL-5-treated 293 cells and assayed the phosphorylation 
on tyrosine residues. While STAT1, 3 and 5a were not acti-
vated by IL-5 (not shown), STAT5b was tyrosine phospho-
rylated in 293 cells after IL-5 stimulation (Fig. ID). Similar 
results were obtained in Rat-1 and 3T3 cells (not shown). 
To assess whether Tyr612 and Tyr577 are important for 
STAT5 induction, we mutated tyrosine 612 to phenylalanine 
(612F) and tyrosine 577 to glycine (577G) in the P627 deletion 
mutant (P627YY). The single mutations of Tyr577 (P627GY) 
or Tyr612 (p627YF) result in a dramatic decrease of phospho-
rylation, while mutation of both residues completely inhibited 
IL-5-induced phosphorylation (Fig. 2A). We next mutated 
tyrosines 577 and 612 in the context of the full-length receptor 
(P881GFYYYY). Interestingly, when stimulated with IL-5, 
this mutant P chain was still phosphorylated (Fig. 2B). This 
indicated that other tyrosines were phosphorylated. To iden-
tify these tyrosines, the same mutations were made in P826 
Fig. 1. IL-5-induced activation of STAT5 and tyrosine phosphorylation of IL-5R p-chain deletion mutants in 293 cells, (a) Structure of the 
full-length IL-5R P-chain and deletion mutants used in this study. Intracellular tyrosine residues (Y) are indicated by numbers, box 1 and box 
2 are indicated by shaded rectangles, the extracellular domains are partially indicated, (b) 293 cells were transfected with the IL-5Ra chain (1 
Ug) and truncated Pc receptors (1 |xg) together with a 4xGAStkCAT reporter construct (2 ug). 24 h post-transfection, IL-5 (10~10 M) was 
added for another 16 h. Fold induction represents CAT activity in IL-5-treated cells relative to untreated cells, and is the mean of three inde-
pendent experiments, (c) 293 cells expressing wild-type or mutant P chains were incubated without (—) or with 5xl0 - 1 0 M hIL-5 (+) for 15 
min at 37°C. Whole-cell lysates were immunoprecipitated with a polyclonal antibody against the P chain, and immunoprecipitates were analysed 
using anti-pY (top panel) or anti-Pc (bottom panel) antibodies. Pc proteins appear as two bands, of which only the upper band is phosphoryl-
ated after IL-5 stimulation. The lower bands might represent incorrectly processed forms of Pc which are not expressed at the cell surface, and 
can therefore not respond to IL-5. (d) 293 cells were transfected with the IL-5Roc and P chain and incubated without (—) or with 5X 10-10 M 
hIL-5 (+) for 15 min at 37°C. HL-60 cells stimulated with GM-CSF served as a positive control. Whole-cell lysates were immunoprecipitated 
with a STAT5b antibody. The immunoprecipitates were analyzed with anti-pY (top panel) or anti-STAT5b (bottom panel). 
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Fig. 2. IL-5 induces phosphorylation of Tyr577, Tyr612, Tyr695 and Tyr750 of the Be chain. 293 cells expressing wild-type or mutant B chains 
were incubated without (—) or with 5X 10~10 M hIL-5 (+) for 15 min at 37°C. B chain phosphorylation was assayed as described for Fig. IC. 
(a) Mutation of Tyr577 (627GY), Tyr612 (627YF) or both (627GF) in the B627 (627YY) context. As described for Fig. IC, B627 appears as two 
bands, of which only the upper band (indicated by an arrowhead) is phosphorylated after IL-5 stimulation, (b) Mutation of Tyr577 and Tyr612 
(GF) in the (3881, B826 and B763 deletion constructs, and mutation of Tyr577, Tyr612 and Tyr695 (GFTY) or Tyr577, Tyr612, Tyr695 and Tyr750 
(GFTA) in the B763 context. B881, B826, and B763 run as a double band (indicated by an arrowhead) in between two unspecific bands. These 
unspecific bands are more obvious in the left panel, since this panel was exposed longer than the B763 panel. 
((3826GFYYY-) and (3763 ((3763GFYY- -), which eliminated 
Tyr866 and Tyr806, respectively. Both these receptor mutants 
are phosphorylated (Fig. 2B). (3763GFYY- - contains only 
two tyrosine residues: Tyr695 and Tyr750. To discriminate be-
tween these, three mutants were constructed: (3763GFTY- -
only containing Tyr750, (3751GFYF- - only containing 
Tyr695, and P763GFTA- - containing no tyrosine residue. 
Phosphorylation studies with these constructs showed that 
both Tyr695 and Tyr750 could be phosphorylated, albeit at 
low levels (Fig. 2B and not shown). Taken together, tyrosine 
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Fig. 3. Tyrosine redundancy in the B chain for ST AT activation. 
293 cells were transfected with 1 ug IL-5R a chain and 1 ug of the 
mutant B receptors together with 2 ug 4xGAStkCAT reporter con-
struct, after which IL-5-induced STAT activation was measured as 
described for Fig. IB. (a) Mutation of Tyr577 (627GY), Tyr612 
(627YF) or both (627GF) in the B627 (627YY) context clearly 
shows that Tyr612 is important for STAT5 activation, (b) Mutation 
of Tyr677 and Tyr612 (GF) in the B881, 0826 and B763 deletion con-
structs and mutation of Tyr577, Tyr612 and Tyr695 (GFTY) or 
Tyr577, Tyr612, Tyr695 and Tyr750 (GFTA) in the B763 (YYYY) con-
text shows that Tyr612, Tyr695 and Tyr750 are able to mediate 
STAT5 activation. 
residues 577, 612, 695, and 750 in the IL-5R(3 are phospho-
rylated upon IL-5 stimulation. 
To determine whether tyrosine phosphorylation of the pc 
chain is involved in STAT5 activation, we tested the different 
mutations in 293 cells. In the context of P627, only mutation 
of Tyr612 (P627YF) resulted in a clear drop in CAT activity 
after IL-5 stimulation, while mutation of only Tyr577 
(P627GY) had no effect (Fig. 3A). The double mutant 
P627GF did not induce any increase CAT activity. Therefore, 
although both tyrosines are phosphorylated after IL-5 stimu-
lation (Fig. 2A), only Tyr612 plays a major role in STAT 
activation in the context of P627. Surprisingly, mutation of 
Tyr612 and Tyr577 in the context of P881, P826 and P763 did 
not result in a decrease in IL-5-induced CAT activity (Fig. 
3B). Moreover, mutants containing only Tyr695 (763 GFYF) 
or Tyr750 (763 GFTY) were capable of inducing STAT activ-
ity (Fig. 3B). Importantly, P763GFTA- - was the only recep-
tor mutant in this panel that is not phosphorylated after IL-5 
stimulation (Fig. 2B) and does not support IL-5-induced CAT 
activity. Therefore, phosphorylation of either Tyr612, Tyr695 or 
Tyr750 is both necessary and sufficient for STAT activation by 
IL-5. 
4. Discussion 
The major conclusion from our study is that tyrosine phos-
phorylation of the IL-5R P chain is essential for endogenous 
STAT5 activation. This is in contrast with previous data 
where tyrosine phosphorylation of the P chain was not im-
portant for STAT activation in COS and BA/F3 cells [11,13]. 
However, in these studies the STAT proteins were overex-
pressed, while we have studied activation of endogenous 
STAT proteins. Interestingly, when STAT proteins are over-
expressed in 293 cells, receptor phosphorylation is dispensable 
for IL-5-induced STAT activation (data not shown). An alter-
native mechanism for activation of overexpressed STAT pro-
teins can be the recruitment of STAT5 to activated JAK2 or 
other cytoplasmic tyrosine kinases without binding to the re-
ceptor, resulting in tyrosine phosphorylation and activation of 
STAT proteins. 
Previous work has shown that Tyr577 and Tyr750 of the P 
chain are phosphorylated in BA/F3 cells after GM-CSF stim-
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ulation [30,31]. Both residues are implicated in the activation 
of the SH2 containing adapter protein She and the phospha-
tase SHP-2 (also known as PTPD1 or Syp). Tyrosine phos-
phorylation of either She and SHP-2 leads to the activation of 
R A S and subsequently to transcriptional activation of the c-
fos gene [30,31]. The tyrosine motifs 612 (YLXL) and 750 
(YXXL) exhibit a clear homology with sequences found in 
other cytokine receptors which are involved in STAT5 activa-
tion [32], while the sequence of Tyr6 9 5 (YVSS) lacks this ho-
mology. The finding that each of these tyrosines was sufficient 
to mediate maximal STAT activity indicates that different 
sequences within a receptor can serve as a binding site for 
STAT5. These data show, together with the involvement of 
Tyr577 and Tyr750 for She and SHP-2 activation, that distinct 
sets of tyrosines are involved in different signaling routes. We 
can also conclude that the activation of a specific signaling 
route can be controlled by multiple tyrosines, showing the 
partial functional redundancy of these residues, as was also 
described for STAT activation by the E P O R and G H R [25-
27]. Finally, the redundancy and specificity of the tyrosine 
residues in the activation of different signal transduction 
routes suggest that these pathways are involved in distinct 
cellular functions. Although STAT5 is implicated to activate 
specific genes involved in proliferation and differentiation of 
hematopoietic cells, the precise function(s) of STAT proteins 
in IL-5 signaling still remains to be elucidated. 
Acknowledgements: We thank Jan Tavernier and Roberto Solari for 
the gift of plasmids and Dilnya Fattah for the gift of hIL-5. This work 
was supported by a research grant from GlaxoWellcome bv. 
References 
[1] Lopez, A.F., Elliott, M.J., Woodcock, J. and Vadas, M.A. (1992) 
Immunol. Today 13, 495-500. 
[2] Ogawa, M. (1993) Blood 81, 2844-2853. 
[3] Sanderson, C.J., Warren, D.J. and Strath, M. (1985) J. Exp. 
Med. 162, 60-74. 
[4] Lopez, A.F., Sanderson, C.J., Gamble, J.R., Campbell, H.D., 
Young, I.G. and Vadas, M.A. (1988) J. Exp. Med. 167, 219-224. 
[5] Fujisawa, T., Abu Ghazaleh, R., Kita, H., Sanderson, C.J. and 
Gleich, G.J. (1990) J. Immunol. 144, 642-646. 
[6] van der Bruggen, T., Kok, P.T.M., Raaijmakers, J.A.M., Ver-
hoeven, A.J., Kessels, R.G.C., Lammers, J.W.J. and Koender-
man, L. (1993) J. Leukocyte Biol. 53, 347-353. 
[7] Chihara, J., Plumas, J., Gruart, V., Tavernier, J., Prin, L., Cap-
ron, A. and Capron, M. (1990) J. Exp. Med. 172, 1347-1351. 
[8] Tavernier, J., Devos, R., Cornelis, S., Tuypens, T., Van der Hey-
den, J., Fiers, W. and Plaetinck, G. (1991) Cell 66, 1175-1184. 
[9] Sato, N., Sakamaki, K., Terada, N., Arai, K.-I. and Miyajima, 
A. (1993) EMBO J. 12, 4181^4-189. 
[10[ 
[11 
[12: 
[13: 
[i4: 
[is: 
tie: 
[17 
[is: 
[is: 
[20 
[21 
[22 
[23: 
P4: 
[25: 
[26 
[27 
[28: 
[29 
[30 
[31 
[32 
Takaki, S., Kanazawa, H., Shiiba, M. and Takatsu, K. (1994) 
Mol. Cell. Biol. 14, 7404-7413. 
Caldenhoven, E., van Dijk, T., Raaijmakers, J.A.M., Lammers, 
J.W.J., Koenderman, L. and de Groot, R.P. (1995) J. Biol. 
Chem. 270, 25778-25784. 
Quelle, F.W., Sato, N., Witthuhn, B.A., Inhorn, R.C., Eder, M., 
Miyajima, A., Griffin, J.D. and Ihle, J.N. (1994) Mol. Cell. Biol. 
14, 4335^4-341. 
Mui, A.L.-F., Wakao, H., O'Farrell, A.-M., Harada, N. and 
Miyajima, A. (1995) EMBO J. 14, 1166-1175. 
Appleby, M.W., Kerner, J.D., Chien, S., Maliszewski, C.R., Bon-
dadaa, S. and Perlmutter, R.G. (1995) J. Exp. Med. 182, 811-
820. 
Pazdrak, K., Schreiber, D., Forsythe, P., Justement, L. and 
Alam, R. (1995) J. Exp. Med. 181, 1827-1834. 
Mano, H., Yamashita, Y., Sato, K., Yazaki, Y. and Hirai, H. 
(1995) Blood 85, 343-350. 
Hanazono, Y., Chiba, S., Sasaki, K., Mano, H., Miyajima, A., 
Arai, K.-I., Yazaki, Y. and Hirai, H. (1993) EMBO J. 12, 1641-
1646. 
Silvennoinen, O., Witthuhn, B.A., Quelle, F.W., Cleveland, J.L., 
Yi, T. and Ihle, J.N. (1993) Proc. Natl. Acad. Sci. USA 90, 8429-
8433. 
van der Bruggen, T., Caldenhoven, E., Kanters, D., Coffer, P., 
Raaijmakers, J.A.M., Lammers, J.W.J. and Koenderman, L. 
(1995) Blood 85, 1442-1448. 
Greenlund, A.C., Farrar, M.A., Viviano, B.L. and Schreiber, 
R.D. (1994) EMBO J. 13, 1591-1609. 
Friedmann, M.C., Migone, T.-S., Russell, S.M. and Leonard, 
W.J. (1996) Proc. Natl. Acad. Sci. USA 93, 2077-2082. 
Hou, J., Schindler, U., Henzel, W.J., Ho, T.C., Brasseur, M. and 
McKnight, S.L. (1994) Science 265, 1701-1706. 
Stahl, N., Farruggella, T.J., Boulton, T.G., Zhong, Z., Darnell, 
J.E.J. and Yancopoulos, G.D. (1995) Science 267, 1349-1353. 
Demoulin, J.-B., Uyttenhove, C , van Roost, E., de Lestre, B., 
Donckers, D., van Snick, J. and Renauld, J.-C. (1996) Mol. Cell. 
Biol. 16, 4710-4716. 
Gobert, S., Chretien, S., Gouilleux, F., Muller, O., Pallard, C , 
Dusanter-Fourt, I., Groner, B., Lacombe, C , Gisselbrecht, S. 
and Mayeux, P. (1996) EMBO J. 15, 2434-2441. 
Quelle, F.W., Wang, D., Nosaka, T., Thierfelder, W.E., Stravo-
podis, D., Weinstein, Y. and Ihle, J.N. (1996) Mol. Cell. Biol. 16, 
1622-1631. 
Smit, L.S., Meyer, D.J., Billestrup, N., Norstedt, G., Schwartz, J. 
and Carter-Su, C. (1996) Mol. Endocrinol. 10, 519-533. 
de Groot, R.P., van Dijk, T.B., Caldenhoven, E., Coffer, P.J., 
Raaijmakers, J.A.M., Lammers, J.-W.J. and Koenderman, L. 
(1997) J. Biol. Chem. 272, 2319-2325. 
Kunkel, T.A. (1985) Proc. Natl. Acad. Sci. USA 82, 488^492. 
Itoh, T., Muto, A., Watanabe, S., Miyajima, A., Yokota, T. and 
Arai, K.-I. (1996) J. Biol. Chem. 271, 7587-7592. 
Inhorn, R.C., Carlesso, N., Durstin, M., Frank, D A . and Grif-
fin, J.D. (1995) Proc. Natl. Acad. Sci. USA 92, 8665-8669. 
May, P., Gerhartz, C , Heesel, B., Welte, T., Doppler, W., 
Graeve, L., Horn, F. and Heinrich, P.C. (1996) FEBS Lett. 
394, 221-226. 
